A E Giuliano

Summary

Affiliation: John Wayne Cancer Institute
Country: USA

Publications

  1. ncbi Tumor characteristics predictive of sentinel node metastases in 105 consecutive patients with invasive lobular carcinoma
    Baiba J Grube
    Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA 90404, USA
    Am J Surg 184:372-6. 2002
  2. ncbi Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors
    Eiji Sunami
    Department of Molecular Oncology, The John Wayne Cancer Institute, Saint John s Health Center, Santa Monica Blvd, Santa Monica, California 90404, USA
    Breast Cancer Res 10:R46. 2008
  3. ncbi Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007
    Armando E Giuliano
    John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Ann Surg Oncol 14:2425-7. 2007
  4. ncbi Sentinel node mapping for breast cancer: progress to date and prospects for the future
    Helen Mabry
    John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Surg Oncol Clin N Am 16:55-70. 2007
  5. ncbi Local and regional control in breast cancer: role of sentinel node biopsy
    Armando E Giuliano
    Margie and Robert E Petersen Breast Cancer Research Program, John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Adv Surg 45:101-16. 2011
  6. ncbi Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer
    A E Giuliano
    Joyce Eisenberg Keefer Breast Center, Division of Surgical Oncology, Statistical Coordinating Unit, Department of Nuclear Medicine, Santa Monica, CA, USA
    J Clin Oncol 18:2553-9. 2000
  7. ncbi Current status of sentinel lymphadenectomy in breast cancer
    A E Giuliano
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California 90404, USA
    Ann Surg Oncol 8:52S-55S. 2001
  8. ncbi Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial
    Armando E Giuliano
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    Ann Surg 252:426-32; discussion 432-3. 2010
  9. ncbi Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial
    Armando E Giuliano
    John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    JAMA 305:569-75. 2011
  10. ncbi Detection of MAGE-A3 in breast cancer patients' sentinel lymph nodes
    R A Wascher
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    Br J Cancer 85:1340-6. 2001

Detail Information

Publications87

  1. ncbi Tumor characteristics predictive of sentinel node metastases in 105 consecutive patients with invasive lobular carcinoma
    Baiba J Grube
    Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA 90404, USA
    Am J Surg 184:372-6. 2002
    ..CONCLUSIONS: SN staging for ILC is feasible and accurate. Receptor status and proliferative indices are not useful markers for metastases. However, large tumor size and presence of angiolymphatic invasion are positive predictors...
  2. ncbi Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors
    Eiji Sunami
    Department of Molecular Oncology, The John Wayne Cancer Institute, Saint John s Health Center, Santa Monica Blvd, Santa Monica, California 90404, USA
    Breast Cancer Res 10:R46. 2008
    ....
  3. ncbi Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007
    Armando E Giuliano
    John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Ann Surg Oncol 14:2425-7. 2007
  4. ncbi Sentinel node mapping for breast cancer: progress to date and prospects for the future
    Helen Mabry
    John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Surg Oncol Clin N Am 16:55-70. 2007
    ..SNB has become the new standard of care for the treatment of early breast cancer...
  5. ncbi Local and regional control in breast cancer: role of sentinel node biopsy
    Armando E Giuliano
    Margie and Robert E Petersen Breast Cancer Research Program, John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Adv Surg 45:101-16. 2011
    ....
  6. ncbi Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer
    A E Giuliano
    Joyce Eisenberg Keefer Breast Center, Division of Surgical Oncology, Statistical Coordinating Unit, Department of Nuclear Medicine, Santa Monica, CA, USA
    J Clin Oncol 18:2553-9. 2000
    ..Therefore, we hypothesized that SLND alone in patients with tumor-negative sentinel nodes would achieve axillary control, with minimal complications...
  7. ncbi Current status of sentinel lymphadenectomy in breast cancer
    A E Giuliano
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California 90404, USA
    Ann Surg Oncol 8:52S-55S. 2001
    ..In other settings, level I and II axillary dissection is essential until the SLND team has achieved consistently accurate results and the institution has established excellent quality control...
  8. ncbi Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial
    Armando E Giuliano
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    Ann Surg 252:426-32; discussion 432-3. 2010
    ..Few studies have examined the outcome of patients who do not undergo ALND for positive SNs. We now report local and regional recurrence information from the American College of Surgeons Oncology Group Z0011 trial...
  9. ncbi Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial
    Armando E Giuliano
    John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    JAMA 305:569-75. 2011
    ..Sentinel lymph node dissection (SLND) accurately identifies nodal metastasis of early breast cancer, but it is not clear whether further nodal dissection affects survival...
  10. ncbi Detection of MAGE-A3 in breast cancer patients' sentinel lymph nodes
    R A Wascher
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    Br J Cancer 85:1340-6. 2001
    ..One half of breast tumours expressed MAGE-A3 mRNA, which has important potential implications for antigen-specific targeted immunotherapy...
  11. ncbi Pathologic examination of sentinel lymph node for breast carcinoma
    R R Turner
    Department of Surgery, John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica California 90404, USA
    World J Surg 25:798-805. 2001
    ..This review discusses our current understanding of the pathologic and molecular techniques for sentinel node examination...
  12. ncbi The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation
    M C Cabot
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    FEBS Lett 431:185-8. 1998
    ..5 microM, cyclosporin A and PSC 833 treatment increased ceramide formation by 20% and 7.5-fold, respectively. These results reveal a new action of PSC 833 which may contribute to its potency as a drug resistance modulator...
  13. ncbi Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes
    J Michael Guenther
    Kaiser Los Angeles Medical Center, Los Angeles, CA, USA
    Arch Surg 138:52-6. 2003
    ..To confirm this observation, we suggest that patients with SN metastases are ideal candidates for trials evaluating the necessity of ALND...
  14. ncbi Role for sentinel lymph node dissection in the management of large (> or = 5 cm) invasive breast cancer
    M H Chung
    Joyce Eisenberg Keefer Breast Center. John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California 90404, USA
    Ann Surg Oncol 8:688-92. 2001
    ..CONCLUSIONS: SLND is feasible and accurate in patients with large breast cancers and clinically negative axillae. Axillary lymph node dissection can be avoided in nearly one third of patients by focused examination of the SLN...
  15. ncbi The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer
    N Habal
    Roy E Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, Santa Monica, CA, USA
    Semin Oncol 28:41-52. 2001
    ..Although SLND has been validated by institutions worldwide, it continues to evolve. The following review will examine current data and controversies surrounding this emerging technology...
  16. ncbi Dermal versus intraparenchymal lymphoscintigraphy of the breast
    P Shen
    Joyce Eisenberg Keefer Breast Cancer Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California 90404, USA
    Ann Surg Oncol 8:241-8. 2001
    ..This finding has implications for injection techniques when lymphatic mapping of the SN is undertaken to stage a breast carcinoma...
  17. ncbi Ceramide glycosylation potentiates cellular multidrug resistance
    Y Y Liu
    John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA 90404, USA
    FASEB J 15:719-30. 2001
    ..This study reveals that GCS is a novel mechanism of multidrug resistance and positions GCS antisense as an innovative force to overcome multidrug resistance in cancer chemotherapy...
  18. ncbi SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells
    M C Cabot
    John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, California 90404, USA
    Cancer Res 59:880-5. 1999
    ..These data demonstrate that PSC 833 has mechanisms of action in addition to P-glycoprotein chemotherapy efflux pumping...
  19. ncbi Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes
    Taku Nakagawa
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, California 90404, USA
    Clin Cancer Res 13:4105-10. 2007
    ....
  20. ncbi Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ACOSOG Z0011 trial
    B J Grube
    Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Semin Surg Oncol 20:230-7. 2001
    ..The historical data comparing ALND to no ALND in clinically node-negative patients is reviewed and discussed in the context of observation for a positive SN. These are the issues underlying the ACOSOG Z0010 and Z0011 trials...
  21. ncbi Underuse of axillary dissection for the management of sentinel node micrometastases in breast cancer
    Nabil Wasif
    John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Arch Surg 145:161-6. 2010
    ..Current American Society of Clinical Oncology guidelines for management of sentinel node micrometastases (SNMM) in breast cancer recommend axillary lymph node dissection (ALND) for all patients...
  22. ncbi Sentinel lymph node biopsy for local recurrence of breast cancer after breast-conserving therapy
    Bret Taback
    Division of Surgical Oncology, Columbia University Medical Center, 177 Fort Washington Avenue, New York, New York 10032, USA
    Ann Surg Oncol 13:1099-104. 2006
    ..This approach illustrates variations in the lymphatic drainage of recurrent breast tumors and may permit the identification of regional metastasis not noted with conventional imaging techniques...
  23. ncbi The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis
    Steven L Chen
    Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute, Saint John s Health Center, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Ann Surg Oncol 14:3378-84. 2007
    ..We hypothesized that the survival of patients with solely micrometastatic disease (N1mi) would be intermediate to patients with 1-3 tumor-positive lymph nodes (N1) and those with no positive lymph nodes (N0)...
  24. ncbi Nonsentinel node metastases in breast cancer patients with isolated tumor cells in the sentinel node: implications for completion axillary node dissection
    Kristine E Calhoun
    The Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Am J Surg 190:588-91. 2005
    ..3% had micrometastases. When ALND was not performed, axillary recurrence was not seen. The low risk of non-SLN disease in this study fails to support the routine use of ALND for ITC-positive SLNs...
  25. ncbi Lymphoscintigraphy and lymphatic mapping for identification of sentinel lymph nodes
    E C Hsueh
    Joyce Eisenberg Keefer Breast Center and the Division of Surgical Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    World J Surg 25:794-7. 2001
    ....
  26. ncbi Microsatellite alterations detected in the serum of early stage breast cancer patients
    B Taback
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Ann N Y Acad Sci 945:22-30. 2001
    ....
  27. ncbi Sentinel lymph node mapping for primary breast cancer
    Lori L Wilson
    Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at St. John's Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Curr Oncol Rep 7:12-7. 2005
    ..We address the current status and future directions of SLND for primary breast cancer...
  28. ncbi What is the value of axillary dissection or sentinel node biopsy in patients with ductal carcinoma in situ?
    Helen Mabry
    Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Am J Surg 192:455-7. 2006
    ..Some surgeons have advocated sentinel node biopsy (SNB) for ductal carcinoma in situ (DCIS). The value of the information obtained is not clear...
  29. ncbi Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis
    Masaru Shinozaki
    Department of Molecular Oncology, John Wayne Cancer Institute and St. John's Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Clin Cancer Res 11:2156-62. 2005
    ....
  30. ncbi Manipulation of the primary breast tumor and the incidence of sentinel node metastases from invasive breast cancer
    Nora M Hansen
    Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, Calif, USA
    Arch Surg 139:634-9; discussion 639-40. 2004
    ..The incidence of sentinel node (SN) metastases from invasive breast cancer might be affected by the technique used to obtain biopsy specimens from the primary tumor before sentinel lymph node dissection...
  31. ncbi The utility of estrogen receptor, progesterone receptor, and Her-2/neu status to predict survival in patients undergoing hepatic resection for breast cancer metastases
    Steve R Martinez
    Department of Surgical Oncology, Division of Gastrointestinal Surgery, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Am J Surg 191:281-3. 2006
    ..Hepatic metastases from breast cancer signal a dismal prognosis, with a median survival of 9.5 months...
  32. ncbi Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells
    Yong Yu Liu
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA, USA
    J Lipid Res 45:933-40. 2004
    ..This study demonstrates that a 20-mer asGCS oligonucleotide effectively reverses MDR in human cancer cells...
  33. ncbi Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells
    Valerie Gouaze-Andersson
    John Wayne Cancer Institute at Saint John s Health Center, Department of Experimental Therapeutics, Santa Monica, CA 90404, USA
    Biochim Biophys Acta 1771:1407-17. 2007
    ..Therefore, ceramide's role as a messenger of cytotoxic response might be linked to the multidrug resistance pathway...
  34. ncbi An update on prognosis in breast cancer patients with extensive axillary disease
    Francesca Hoehne
    Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California 90404, USA
    Breast J 14:76-80. 2008
    ..14 (95% confidence interval: 0.04-0.46). In our study, patients with at least 10 positive axillary LN had a 5-year survival of 71.9% which may be due to the improvements in local and systemic therapy...
  35. ncbi Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes
    Nabil Wasif
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA, USA
    Ann Surg Oncol 17:1862-9. 2010
    ..Does delayed diagnosis of ILC affect survival? We used a national registry to compare outcomes of patients with stage-matched ILC and IDC...
  36. ncbi Survey of ASCO members on management of sentinel node micrometastases in breast cancer: variation in treatment recommendations according to specialty
    Nabil Wasif
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA, USA
    Ann Surg Oncol 16:2442-9. 2009
    ..We hypothesized that variation exists in adherence to these guidelines and management of SNMM as a result of the medical specialty of the treating physician...
  37. ncbi The time has come to change the algorithm for the surgical management of early breast cancer
    Nora M Hansen
    Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at St John s Health Center, Santa Monica, CA 90404, USA
    Arch Surg 137:1131-5. 2002
    ..If the sentinel lymph nodes (SNs) draining a primary invasive breast cancer are free of tumor, then axillary lymph node dissection is not necessary for management of disease...
  38. ncbi Long-term morbidity of sentinel node biopsy versus complete axillary dissection for unilateral breast cancer
    Rebecca Crane-Okada
    Department of Surgical Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA, USA
    Ann Surg Oncol 15:1996-2005. 2008
    ..The purpose of this study was to compare long-term morbidity after SLNB or ALND and breast-conservation surgery...
  39. ncbi Surgical management of breast cancer in the elderly patient
    B J Grube
    Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Am J Surg 182:359-64. 2001
    ..4 months and 91% for the > or = 70 years group at 44.5 months. CONCLUSIONS: In our population the presentation, surgical treatment, and survival from breast cancer is similar in older and younger women...
  40. ncbi Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training
    Roderick R Turner
    Department of Pathology, Saint John s Health Center, 1328 Twenty Second St, Santa Monica, CA 90404, USA
    J Clin Oncol 26:258-63. 2008
    ..We sought to determine whether a set of clearly defined histologic criteria could lead to reproducible nodal classification by pathologists...
  41. ncbi Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis
    Taku Nakagawa
    Department of Molecular Oncology, Division of Biostatistics, and Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    Cancer Res 66:11825-30. 2006
    ..016 and 0.0083, respectively). ProteinChip array analysis identified differential protein peaks in primary breast cancers that predict the presence and number of ALN metastases and non-SLN status...
  42. ncbi Impact of micrometastases in the sentinel node of patients with invasive breast cancer
    Nora M Hansen
    John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    J Clin Oncol 27:4679-84. 2009
    ..This study is based on the new sixth edition of the American Joint Committee on Cancer (AJCC) staging criteria...
  43. ncbi Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs
    Valerie Gouaze
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California 90404, USA
    Cancer Res 65:3861-7. 2005
    ..The data suggest that lipids play a role in the expression of multidrug resistance...
  44. ncbi Sentinel node in the era of neoadjuvant therapy and locally advanced breast cancer
    Steven D Trocha
    Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Blvd Suite, 113, Santa Monica, CA, 90404, USA
    Surg Oncol 12:271-6. 2003
    ....
  45. ncbi Taxol-induced ceramide generation and apoptosis in human breast cancer cells
    A G Charles
    John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, 2200 Santa Monica Blvd, Santa Monica CA 90404, USA
    Cancer Chemother Pharmacol 47:444-50. 2001
    ..This is of relevance to drug mechanism studies, as ceramide is a known messenger of apoptosis. Clinical use of Taxol with ceramide-enhancing agents may maximize cytotoxic potential...
  46. ncbi Prediction of breast tumor progression by integrity of free circulating DNA in serum
    Naoyuki Umetani
    Department of Molecular Oncology and the Joyce Eisenberg Breast Center, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    J Clin Oncol 24:4270-6. 2006
    ..0002 and P < .0001, respectively). CONCLUSION: Integrity of serum circulating DNA is a promising molecular biomarker for detecting breast cancer tumor progression and regional LN metastases...
  47. ncbi FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer
    PARTHA S RAY
    Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Cancer Res 70:3870-6. 2010
    ..Our findings identify FOXC1 as a theranostic biomarker that is specific for BLBC, offering not only a potential prognostic candidate but also a potential molecular therapeutic target in this breast cancer subtype...
  48. ncbi MRI versus ultrasonography and mammography for preoperative assessment of breast cancer
    Nabil Wasif
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California 90404, USA
    Am Surg 75:970-5. 2009
    ..We conclude that MRI is more accurate than either ultrasonography or mammography for assessment of the size of primary breast cancer presenting as a mass...
  49. ncbi Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy
    Valerie Gouaze
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California 90404, USA
    Mol Cancer Ther 3:633-9. 2004
    ..A possible connection between glucosylceramide synthase and P-gp in drug resistance biology is suggested...
  50. ncbi Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma
    Joseph Kim
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint Johns Hospital, Santa Monica, CA 90404, USA
    Ann Surg 244:799-804. 2006
    ..To define the role of BRAF gene mutation in the progression of papillary thyroid carcinoma...
  51. ncbi B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis
    Takaaki Arigami
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA, USA
    Ann Surg 252:1044-51. 2010
    ..We hypothesized that B7-H3, a coinhibitory factor, is expressed by primary breast cancer cells and associated with metastasis to regional tumor-draining lymph nodes...
  52. ncbi FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-κB signaling
    J Wang
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA, USA
    Oncogene 31:4798-802. 2012
    ..These results suggest that BLBC cells may rely on FOXC1-driven NF-κB signaling. Interventions of this pathway may provide modalities for the treatment of BLBC...
  53. ncbi Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease
    B Taback
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Cancer Res 61:8845-50. 2001
    ..018). A multimarker reverse transcription-PCR assay that correlates with known clinicopathological prognostic parameters may have potential clinical utility by monitoring tumor progression with a blood test...
  54. ncbi Long-term management and outcome of parathyroidectomy for sporadic primary multiple-gland disease
    D M Rose
    John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Arch Surg 136:621-6. 2001
    ..Selective subtotal parathyroidectomy can yield excellent long-term results in patients with multiple-gland disease...
  55. ncbi Recognition of an epitope of a breast cancer antigen by human antibody
    J Cao
    Department of Biotechnology Sciences, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    Breast Cancer Res Treat 53:279-90. 1999
    ..001). These results suggest that KASIFLK or its cross-reactive epitope is a breast cancer antigen and is immunogenic in humans...
  56. ncbi Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer
    Naoyuki Umetani
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    Oncogene 24:4721-7. 2005
    ..ID4 mRNA level was suppressed in hypermethylated cancer specimens (P=0.014). ID4 may play an important suppressive role in tumor progression, and its silencing by hypermethylation may increase the risk of regional lymph node metastasis...
  57. ncbi Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer
    Eiji Sunami
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California, USA
    Ann N Y Acad Sci 1137:171-4. 2008
    ..This preliminary study demonstrates the potential clinical utility of LINE1 copy numbers in breast cancer patients...
  58. ncbi Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients
    Bret Taback
    Department of Molecular Oncology, Joyce Eisenberg-Keefer Breast Center, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Cancer Res 63:1884-7. 2003
    ....
  59. ncbi Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer
    Robert A Wascher
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Clin Cancer Res 9:1427-35. 2003
    ..CONCLUSIONS: STC-1 is proposed as a novel, specific, and clinically useful molecular marker for detecting occult breast cancer cells in the BM and blood...
  60. ncbi The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer
    Nancy C Greep
    Department of Skeletal Health, The John Wayne Cancer Institute at Saint John's Hospital, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Am J Med 114:653-9. 2003
    ..Whether this effect is caused by adjuvant chemotherapy remains to be determined...
  61. ncbi Skin-sparing mastectomy. specialty bias and worldwide lack of consensus
    Richard J Bleicher
    John Wayne Cancer Institute, Saint John's Hospital and Health Center, Santa Monica, California 90404, USA
    Cancer 98:2316-21. 2003
    ..Although these results were indicative of only those responding, education about SSM is needed across specialties and in other countries if the procedure is to be widely accepted...
  62. ncbi The selective use of sentinel node biopsy in ductal carcinoma in situ
    Richard J Bleicher
    John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    Arch Surg 138:489. 2003
  63. ncbi Molecular lymphatic mapping of the sentinel lymph node
    Bret Taback
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, California 90404, USA
    Am J Pathol 161:1153-61. 2002
    ..MLM in conjunction with a conventional mapping agent can be used as a valuable asset for molecular assessment of the SLN and retrospective analysis of paraffin-embedded specimens...
  64. ncbi Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients
    Bret Taback
    Division of Surgical Oncology, Columbia University Medical Center, New York, New York 10032, USA
    Ann N Y Acad Sci 1075:211-21. 2006
    ..This study demonstrates the novel finding of tumor-associated epigenetic markers in BM aspirates/blood and their potential role as targets for molecular detection...
  65. ncbi Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches
    Jacqueline V Chapman
    John Wayne Cancer Institute at Saint John s Health Center, Department of Experimental Therapeutics, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Biochem Pharmacol 80:308-15. 2010
    ..We propose that use of tamoxifen and other P-glycoprotein antagonists can be an effective means for enhancing cytotoxic potential of short-chain ceramides in the treatment of cancer...
  66. ncbi American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer
    Gary H Lyman
    University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    J Clin Oncol 23:7703-20. 2005
    ..To develop a guideline for the use of sentinel node biopsy (SNB) in early stage breast cancer...
  67. ncbi The results of the Department of Defense's breast lymphatic mapping study
    David A Litvak
    Ann Surg Oncol 9:428-9. 2002
  68. ncbi Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis
    Theodore Kim
    Department of Medicine, Tufts-New England Medical Center, Boston, Massachusetts, USA
    Cancer 106:4-16. 2006
    ..009). CONCLUSIONS: Lymphatic mapping with SLN biopsy is used widely to reduce the complications associated with ALND in patients with low-risk breast carcinoma. This systematic review revealed a wide variation in test performance...
  69. ncbi Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011
    John A Olson
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 26:3530-5. 2008
    ..The impact of the timing of cALND on pathologic results and complications in these patients has not been examined...
  70. ncbi Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania
    Gordon F Schwartz
    Jefferson Medical College, Philadelphia, Pennsylvania, USA
    Cancer 94:2542-51. 2002
  71. ncbi A role for ceramide in driving cancer cell resistance to doxorubicin
    Yong Yu Liu
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, 700 University Ave, Monroe, LA 71209, USA
    FASEB J 22:2541-51. 2008
    ..These data indicate that ceramide-governed GCS gene expression drives cellular resistance to doxorubicin...
  72. ncbi Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer
    Katherine E Posther
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Ann Surg 242:593-9; discussion 599-602. 2005
    ....
  73. ncbi The current role of sentinel node biopsy in the treatment of breast cancer
    Baiba J Grube
    Department of Surgery, University of Texas Medical Branch, Galveston, Texas, USA
    Adv Surg 38:121-66. 2004
  74. ncbi The practical value of prediction: a semireliable assistant
    Helen Mabry
    Ann Surg Oncol 13:282-4. 2006
  75. ncbi Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial
    Lee Gravatt Wilke
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Ann Surg Oncol 13:491-500. 2006
    ..CONCLUSIONS: This study provides a prospective assessment of the sentinel lymph node biopsy procedure, as performed by a wide range of surgeons, demonstrating a low complication rate...
  76. ncbi Sentinel lymph node dissection and the current status of American trials on breast lymphatic mapping
    Katherine E Posther
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Semin Oncol 31:426-36. 2004
    ..Surgeon participation is crucial to the ongoing success of clinical trials in the field of breast cancer surgery...
  77. ncbi Accelerated partial breast irradiation after conservative surgery for breast cancer
    Henry M Kuerer
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg 239:338-51. 2004
    ..To critically review the theoretical and actual risks and benefits of accelerated partial breast irradiation (APBI) after breast-conserving surgery...
  78. ncbi Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study
    Rowan T Chlebowski
    Department of Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 West Carson St, Building J 3, Torrance, CA 90502 2064, USA
    J Natl Cancer Inst 98:1767-76. 2006
    ..We carried out a randomized, prospective, multicenter clinical trial to test the effect of a dietary intervention designed to reduce fat intake in women with resected, early-stage breast cancer receiving conventional cancer management...
  79. ncbi Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit
    Katrina H Moore
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, MRI 1026, New York, NY 10021, USA
    Ann Surg Oncol 14:2911-7. 2007
    ..Although it is well established that nodal status for invasive disease is prognostically important, the clinical relevance of a positive SLN in patients with DCIS remains undetermined...
  80. ncbi Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011
    Anthony Lucci
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:3657-63. 2007
    ..The current study compares complications associated with SLN dissection (SLND) plus ALND, versus SLND alone...
  81. ncbi Sentinel lymphadenectomy: a new alternative for managing early breast cancer
    Arie Bitterman
    Department of Surgery A, Carmel Medical Center, Haifa, Israel
    Isr Med Assoc J 4:803-9. 2002
  82. ncbi A randomized clinical trial on sentinel lymph node dissection versus axillary dissection: a matter of technique
    Laura Kruper
    Ann Surg 247:214-6. 2008
  83. ncbi Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer
    A Marilyn Leitch
    Department of Surgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9155, USA
    Am J Surg 190:539-42. 2005
    ..This report elucidates factors influencing patient accrual...
  84. ncbi SSO approved training programs in breast cancer care
    Helen Mabry
    J Surg Oncol 97:99-100. 2008
  85. ncbi Does breast massage push tumor cells into sentinel nodes?
    Roderick R Turner
    Am J Surg Pathol 29:1254-5; author reply 1255-6. 2005
  86. ncbi Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast April 19 to 22, 2001, Philadelphia, Pennsylvania
    Gordon F Schwartz
    Jefferson Medical College, Philadelphia, PA 19107, USA
    Hum Pathol 33:579-89. 2002
    ..This report summarizes the deliberations of the group and promotes its current guidelines for the integration of this new technique into contemporary clinical practice...
  87. ncbi N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing
    Hongtao Wang
    Childrens Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Mol Cancer Ther 7:2967-76. 2008
    ..These studies suggest that enhanced clinical efficacy of 4-HPR may be realized through regimens containing agents that modulate sphingoid base metabolism...